Skip to main content
Kevin David, MD, Oncology, New Brunswick, NJ

KevinAndrewDavidMD

Oncology New Brunswick, NJ

Hematologic Oncology

Assistant Professor, Medicine, UMDNJ-Robert Wood Johnson Medical School

Dr. David is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. David's full profile

Already have an account?

  • Office

    195 Little Albany St
    New Brunswick, NJ 08901
    Phone+1 732-235-6777
    Fax+1 732-212-0713

Education & Training

  • McGaw Medical Center of Northwestern University
    McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2002 - 2005
  • Columbia University Vagelos College of Physicians and Surgeons
    Columbia University Vagelos College of Physicians and SurgeonsClass of 2002

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2005 - 2026
  • NJ State Medical License
    NJ State Medical License 2009 - 2025
  • PA State Medical License
    PA State Medical License 2024 - 2024
  • IL State Medical License
    IL State Medical License 2006 - 2011
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma
    Kevin A. David, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0408
    Kevin A. David, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
    Kevin A. David, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malig... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Blood Cancer Cures and Care: Addressing Leukemia and Lymphoma
    Blood Cancer Cures and Care: Addressing Leukemia and LymphomaSeptember 9th, 2021
  • Analyzing Outcomes of Older Patients with Primary Central Nervous System Lymphoma
    Analyzing Outcomes of Older Patients with Primary Central Nervous System LymphomaDecember 7th, 2020
  • Retrospective Analysis Identifies Need for Better Classification of Rare Lymphoma
    Retrospective Analysis Identifies Need for Better Classification of Rare LymphomaDecember 4th, 2019
  • Join now to see all